eNeurologicalSci最新文献_第5页

Deterioration of preexisting myoclonus following nifedipine use in parkinsonian syndrome: A case report 硝苯地平治疗帕金森综合征后原有肌阵挛恶化1例报告。

eNeurologicalSci Pub Date : 2024-12-15 DOI: 10.1016/j.ensci.2024.100545

Gohei Yamada , Takanari Toyoda , Eiichi Katada , Noriyuki Matsukawa

{"title":"Deterioration of preexisting myoclonus following nifedipine use in parkinsonian syndrome: A case report","authors":"Gohei Yamada , Takanari Toyoda , Eiichi Katada , Noriyuki Matsukawa","doi":"10.1016/j.ensci.2024.100545","DOIUrl":"10.1016/j.ensci.2024.100545","url":null,"abstract":"<div><div>L-type calcium channel antagonists are uncommon causes of myoclonus, and the underlying mechanism remains unclear. Here, we report a case of parkinsonian syndrome with deterioration of preexisting myoclonus after nifedipine use. A 96-year-old woman was administered a single dose of sustained-release nifedipine for chest pain. One hour later, the patient developed shock-like jerky movements in the trunk and upper and lower limbs. Neurological examination revealed myoclonus, intention tremor in both hands, facial hypomimia, stooped posture, short stride length, absent arm swing during walking, and muscle rigidity in the neck, left arm, and both legs. Brain magnetic resonance imaging showed no causative lesions, suggesting a nifedipine-induced movement disorder. Myoclonic movements almost completely resolved within 24 h. Despite no further administration of nifedipine, a neurological examination one week later revealed parkinsonism with mild myoclonus and intention tremor. It appeared that preexisting myoclonus and intention tremor transiently worsened with nifedipine use. The patient was diagnosed with parkinsonian syndrome with deterioration of myoclonus due to nifedipine administration. This case suggests that the corticostriatal pathways may have already been impaired and were further affected by nifedipine. Nifedipine-induced alterations in dopaminergic and serotonergic systems may have contributed to the deterioration of myoclonus and intention tremor. When patients present with myoclonus after taking an L-type calcium channel antagonist, underlying neurological disorders should be carefully investigated.</div></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"38 ","pages":"Article 100545"},"PeriodicalIF":0.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bilateral foot drop as presenting feature of facioscapulohumeral muscular dystrophy type 1 双侧足下垂为1型面肩肱肌营养不良的表现特征。

eNeurologicalSci Pub Date : 2024-12-13 DOI: 10.1016/j.ensci.2024.100546

Martin Krenn , Veronika Vetchy , Gregor Kasprian , Wolfgang Grisold

引用次数: 0

Neuroepidemiology: Basic concepts and population surveys 神经流行病学：基本概念和人口调查。

eNeurologicalSci Pub Date : 2024-12-03 DOI: 10.1016/j.ensci.2024.100544

Walter A. Rocca

引用次数: 0

Oral minocycline therapy as first-line treatment in patients with Myalgic encephalomyelitis and long COVID: A pilot study 口服二甲胺四环素作为肌痛性脑脊髓炎和长COVID患者的一线治疗：一项初步研究。

eNeurologicalSci Pub Date : 2024-12-02 DOI: 10.1016/j.ensci.2024.100537

Kunihisa Miwa

{"title":"Oral minocycline therapy as first-line treatment in patients with Myalgic encephalomyelitis and long COVID: A pilot study","authors":"Kunihisa Miwa","doi":"10.1016/j.ensci.2024.100537","DOIUrl":"10.1016/j.ensci.2024.100537","url":null,"abstract":"<div><h3>Background</h3><div>Myalgic encephalomyelitis (ME) is associated with long COVID and also untoward sequelae after anti-coronavirus vaccination. Recently, oral minocycline therapy has been reported to ameliorate symptoms in patients with ME, particularly at the initial stage of the disease.</div></div><div><h3>Methods</h3><div>Oral minocycline (100 mg × 2 on the first day, followed by 100 mg/day for 41 days) was administered to 55 patients with ME that emerged during the “Corona era,” including 19 patients with long COVID and 5 patients diagnosed with untoward sequalae following coronavirus vaccination.</div></div><div><h3>Results</h3><div>Acute adverse effects including nausea and/or dizziness caused four (7 %) patients to discontinue treatment in the first few days. Among the other 51 patients who completed therapy, favorable effects were observed, including a decrease in performance status score or index for restricted activities of daily living ≥2 points in 41 (80 %) patients. Disease duration was inversely associated with the favorable therapeutic effects (<em>p</em> = 0.02) and the disease duration within 6 months was significantly associated with the favorable therapeutic effects (27/30, 90 %, <em>p</em> = 0.02, hazard ratio: 3.6, 95 % confidence interval, 1.2<strong>–</strong>10.6). The favorable effects were observed in 16 (89 %) of 18 patients with long COVID. Significant amelioration of subjective symptoms of fatigue, post-exertional malaise, unrefreshing sleep, brain fog, disequilibrium, orthostatic intolerance, and neuropathic pain were observed.</div></div><div><h3>Conclusions</h3><div>Oral minocycline was effective at ameliorating symptoms in patients with ME including long COVID and post-coronavirus vaccination sequalae. It represents an effective first-line therapeutic option for these patients in the initial stage.</div></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"38 ","pages":"Article 100537"},"PeriodicalIF":0.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuropathy and the metabolic syndrome 神经病变和代谢综合征。

eNeurologicalSci Pub Date : 2024-11-28 DOI: 10.1016/j.ensci.2024.100542

Nicoló Piccolo , Astrid Wiggers , Emily J. Koubek, Eva L. Feldman

引用次数: 0

Impact of COVID-19 on functional, cognitive, neuropsychiatric, and health-related outcomes in patients with dementia: A systematic review COVID-19对痴呆患者功能、认知、神经精神和健康相关结局的影响：一项系统综述

eNeurologicalSci Pub Date : 2024-11-21 DOI: 10.1016/j.ensci.2024.100539

Lucia Crivelli , Andrea Winkler , Greta Keller , Simone Beretta , Ismael Luis Calandri , Wouter De Groote , Arianna Fornari , Jennifer Frontera , Miia Kivipelto , Ana Sabsil Lopez-Rocha , Francesca Mangialasche , Daniel Munblit , Katie Palmer , Alla Guekht , Ricardo Allegri

{"title":"Impact of COVID-19 on functional, cognitive, neuropsychiatric, and health-related outcomes in patients with dementia: A systematic review","authors":"Lucia Crivelli , Andrea Winkler , Greta Keller , Simone Beretta , Ismael Luis Calandri , Wouter De Groote , Arianna Fornari , Jennifer Frontera , Miia Kivipelto , Ana Sabsil Lopez-Rocha , Francesca Mangialasche , Daniel Munblit , Katie Palmer , Alla Guekht , Ricardo Allegri","doi":"10.1016/j.ensci.2024.100539","DOIUrl":"10.1016/j.ensci.2024.100539","url":null,"abstract":"<div><h3>Background</h3><div>This systematic review analyzes the impact of COVID-19 on dementia patients' functional, cognitive, neuropsychiatric, and health related outcomes. It hypothesizes that dementia patients infected with SARS-CoV-2experience more pronounced deterioration compared to those who are uninfected.</div></div><div><h3>Methods</h3><div>Research from 01/03/2020 to 07/10/2023 was conducted using Medline, Web of Science, and Embase databases, and adhering to PRISMA guidelines and the PICO framework. The study aimed to determine if SARS-CoV-2 infection is associated with worse outcomes in dementia patients. The protocol is registered in PROSPERO (CRD42022352481), and bias was evaluated using the Newcastle-Ottawa Scale.</div></div><div><h3>Results</h3><div>Among 198 studies reviewed, only three met the criteria. Chen et al. (2023) identified higher mortality in SARS-CoV-2-infected dementia patients, while Merla et al. (2023) observed faster cognitive decline in infected individuals with increased hospital admissions. Additionally, Cascini et al. (2022) reported an increased risk of infection and significantly elevated mortality in dementia patients, highlighting comorbidities and antipsychotic medication use as key risk factors.</div></div><div><h3>Conclusion</h3><div>These limited data suggest higher mortality and cognitive decline in dementia patients following COVID-19, underscoring the need for extensive research in this area.</div></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"38 ","pages":"Article 100539"},"PeriodicalIF":0.0,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11663964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myasthenia gravis: The evolving therapeutic landscape 重症肌无力：不断发展的治疗方法

eNeurologicalSci Pub Date : 2024-11-19 DOI: 10.1016/j.ensci.2024.100541

Gil I. Wolfe, Jonathan E. Hanson, Nicholas J. Silvestri

引用次数: 0

Thalamic deep brain stimulation for postural tremor caused by hyperthermia-induced cerebellar dysfunction: A case report 丘脑深部脑刺激治疗高热引起的小脑功能障碍导致的姿势性震颤：病例报告

eNeurologicalSci Pub Date : 2024-11-17 DOI: 10.1016/j.ensci.2024.100536

Mitsuyoshi Tamura , Shigeki Hirano , Yoshihisa Kitayama , Marie Morooka , Tomoki Suichi , Kazumoto Shibuya , Yoshinori Higuchi , Satoshi Kuwabara

引用次数: 0

Neurobehavioral features in medication-overuse headache 药物滥用性头痛的神经行为特征

eNeurologicalSci Pub Date : 2024-11-17 DOI: 10.1016/j.ensci.2024.100538

Franz Riederer , Roberto Pirrotta , Chantal Martin Soelch , Andreas R. Gantenbein , Adrian Scutelnic , Antonia Klein , Christoph J. Schankin , Peter S. Sándor

{"title":"Neurobehavioral features in medication-overuse headache","authors":"Franz Riederer , Roberto Pirrotta , Chantal Martin Soelch , Andreas R. Gantenbein , Adrian Scutelnic , Antonia Klein , Christoph J. Schankin , Peter S. Sándor","doi":"10.1016/j.ensci.2024.100538","DOIUrl":"10.1016/j.ensci.2024.100538","url":null,"abstract":"<div><h3>Background</h3><div>Medication-overuse headache (MOH) has been related to the spectrum of dependence behavior and impaired orbitofrontal cortex function. Alexithymia is a trait comprising deficits in identifying self-emotions and perception. It was the aim of the study to investigate impulsivity and alexithymia, in patients with MOH and perform correlations with cerebral grey matter.</div></div><div><h3>Material and methods</h3><div>Patients with chronic migraine and MOH according to ICHD criteria from a tertiary headache clinic and healthy controls were investigated by a single psychiatrist, using clinical scales for self-control (BIS-11) and alexithymia (TAS-20) and screened for dependence based on DSM-IV criteria. Correlations of BIS-11 and TAS-20 with cerebral grey matter were analysed with the SPM based toolbox CAT12, using high resolution T1weighted MRI-Sequences acquired on a 3 T scanner.</div></div><div><h3>Results</h3><div>MRI data were available from 30 MOH patients (24 women) and 47 healthy controls (26 women). MOH patients had increased impulsivity (62.2 ± 11.1 vs. 55.7 ± 7.2; <em>p</em> = 0.007) and alexithymia (49.8 ± 14.8 vs. 38.0 ± 6.5; <em>p</em> < 0.001). Analyzing only women, the results remained significant. Ninety percent of patients fulfilled DSM-IV criteria for substance dependence. There was a positive correlation between impulsivity and grey matter in the left middle orbital gyrus in healthy controls but not in patients (<em>p</em> < 0.05, corrected). No correlations with alexithymia and cerebral grey matter were found.</div></div><div><h3>Conclusions</h3><div>The present study suggests a neurobehavioral basis for MOH, consisting of impaired impulse control, and self-perception along with features of substance dependence. Although decreased orbitofrontal cortex volume was confirmed in this MOH cohort, impulsivity and alexithymia were not correlated with this structural abnormality.</div></div>","PeriodicalId":37974,"journal":{"name":"eNeurologicalSci","volume":"37 ","pages":"Article 100538"},"PeriodicalIF":0.0,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142699413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

World neurology updates: Other primary headache disorder – Treatment 世界神经病学最新进展：其他原发性头痛疾病 - 治疗

eNeurologicalSci Pub Date : 2024-11-13 DOI: 10.1016/j.ensci.2024.100535

Sina Marzoughi , Peter J. Goadsby

引用次数: 0